Advaxis, Inc.
https://www.advaxis.com/home
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Advaxis, Inc.
Keeping Track: Gilead Gets CRL For Bulevirtide, CytoDyn Withdraws Leronlimab; Eye and CNS Drug Submissions
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Advaxis To Seek New Life In Merger With Ayala
The new company will focus mainly on Ayala’s lead candidate for desmoid tumors, but minority owner Advaxis will take over management.
Neoantigen Cancer Vaccine Helps BioNTech Advance Oncology Ambitions
After many years of failures and setbacks, neoantigen-targeting immunotherapies are gaining momentum, with BioNTech and Roche among the frontrunners.
‘Femtech’ Evolving Beyond Periods, Pregnancy And Postpartum
Digital female-centric primary and preventive care and fertility support were top-funded women’s health segments in 2021, drawing $668m and $330m in investments, respectively. Going forward, experts anticipate innovation to address unmet needs related to menopause, vaginal microbiome, endometriosis, and other chronic conditions, and surgeries such as hysterectomies and mastectomies.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Other Names / Subsidiaries
-
- Ayala Pharmaceuticals, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice